Citius Pharmaceuticals
CTXR
39 hedge funds and large institutions have $1.34M invested in Citius Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
73% more capital invested
Capital invested by funds: $773K → $1.34M (+$564K)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
15% more funds holding
Funds holding: 34 → 39 (+5)
4.62% more ownership
Funds ownership: 3.67% → 8.29% (+4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Heights Capital Management
San Francisco,
California
|
+$1M |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$114K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$63.2K |
| 4 |
Two Sigma Investments
New York
|
+$48.8K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$44.1K |
| 2 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$31.3K |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$12K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$11K |
| 5 |
Jane Street
New York
|
-$1.16K |
CTXR Hedge Fund Activity: Q4 2025 in Review
39 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q4 2025, worth a combined $1.34M — up 73% from $773K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CTXR positions and 4 closed out — a net gain of 5 holders — while 8 added to existing stakes and 6 trimmed.
The largest buyer was Heights Capital Management, opening a new position worth an estimated $1M. The largest seller was Susquehanna International Group, cutting an estimated $44.1K.
- 39 institutional investors held Citius Pharmaceuticals (CTXR) as of Q4 2025, up from 34 in Q3 2025.
- Funds reported $1.34M of Citius Pharmaceuticals stock for Q4 2025, up 73% quarter-over-quarter.
- 9 funds opened new Citius Pharmaceuticals positions in Q4 2025 and 4 closed out, a net change of +5 holders.
- The largest Citius Pharmaceuticals buyer in Q4 2025 was Heights Capital Management, an estimated $1M added.
- The largest Citius Pharmaceuticals seller in Q4 2025 was Susquehanna International Group, an estimated $44.1K sold.
Based on aggregated 13F filings for Q4 2025.